MiRNAs and snoRNAs in Bone Metastasis: Functional Roles and Clinical Potential.
circulating biomarker
extracellular vesicle
non-coding RNA
osteoblast
osteoclast
post-transcriptional gene regulation
pre-metastatic niche
rRNA chemical modifications
translation
vicious cycle
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Dec 2022
30 Dec 2022
Historique:
received:
26
10
2022
revised:
19
12
2022
accepted:
26
12
2022
entrez:
8
1
2023
pubmed:
9
1
2023
medline:
9
1
2023
Statut:
epublish
Résumé
Bone is a frequent site of metastasis. Bone metastasis is associated with a short-term prognosis in cancer patients, and current treatments aim to slow its growth, but are rarely curative. Thus, revealing molecular mechanisms that explain why metastatic cells are attracted to the bone micro-environment, and how they successfully settle in the bone marrow-taking advantage over bone resident cells-and grow into macro-metastasis, is essential to propose new therapeutic approaches. MicroRNAs and snoRNAs are two classes of small non-coding RNAs that post-transcriptionally regulate gene expression. Recently, microRNAs and snoRNAs have been pointed out as important players in bone metastasis by (i) preparing the pre-metastatic niche, directly and indirectly affecting the activities of osteoclasts and osteoblasts, (ii) promoting metastatic properties within cancer cells, and (iii) acting as mediators within cells to support cancer cell growth in bone. This review aims to highlight the importance of microRNAs and snoRNAs in metastasis, specifically in bone, and how their roles can be linked together. We then discuss how microRNAs and snoRNAs are secreted by cancer cells and be found as extracellular vesicle cargo. Finally, we provide evidence of how microRNAs and snoRNAs can be potential therapeutic targets, at least in pre-clinical settings, and how their detection in liquid biopsies can be a useful diagnostic and/or prognostic biomarker to predict the risk of relapse in cancer patients.
Identifiants
pubmed: 36612237
pii: cancers15010242
doi: 10.3390/cancers15010242
pmc: PMC9818347
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Inserm
ID : 20CN063-00
Organisme : Claude Bernard University Lyon 1
ID : ANR-10-LABX-61
Organisme : Claude Bernard University Lyon 1
ID : ANR-11-IDEX-0007
Organisme : Weston Park Cancer Charity
ID : CA163
Organisme : INCa
ID : PLBio 2019-138
Organisme : INCa
ID : PRT-K 2018-024
Références
Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188501
pubmed: 33400969
Cancers (Basel). 2021 Sep 06;13(17):
pubmed: 34503302
Br J Cancer. 2020 May;122(11):1630-1637
pubmed: 32238921
Nature. 2007 Oct 11;449(7163):682-8
pubmed: 17898713
J Cell Biol. 1994 Dec;127(6 Pt 1):1755-66
pubmed: 7798324
Nucleic Acids Res. 2011 Jan;39(2):675-86
pubmed: 20846955
Int J Genomics. 2017;2017:6496570
pubmed: 29038786
Cancers (Basel). 2020 Oct 09;12(10):
pubmed: 33050237
Curr Osteoporos Rep. 2021 Jun;19(3):256-263
pubmed: 33830428
Cancers (Basel). 2019 Mar 07;11(3):
pubmed: 30866509
Clin Chem. 2010 Nov;56(11):1733-41
pubmed: 20847327
J Exp Clin Cancer Res. 2015 May 15;34:49
pubmed: 25975345
Clin Chem Lab Med. 2021 Feb 05;59(7):1181-1200
pubmed: 33544478
Nat Commun. 2021 Aug 31;12(1):5196
pubmed: 34465793
Neuron. 2007 Jun 7;54(5):813-29
pubmed: 17553428
NPJ Breast Cancer. 2017 Jul 10;3:25
pubmed: 28702505
Transl Lung Cancer Res. 2021 Feb;10(2):1165-1185
pubmed: 33718054
Trends Cancer. 2019 Feb;5(2):95-110
pubmed: 30755309
Br J Pharmacol. 2021 May;178(9):1936-1954
pubmed: 31423566
J Extracell Vesicles. 2021 Jan;10(3):e12056
pubmed: 33489015
Oncotarget. 2015 Jul 10;6(19):17430-44
pubmed: 26041889
Gastroenterology. 2017 Jul;153(1):292-306.e2
pubmed: 28390868
Nucleic Acids Res. 2011 Feb;39(3):e13
pubmed: 21062825
Nucleic Acids Res. 2022 Jan 7;50(D1):D111-D117
pubmed: 34387689
Cancers (Basel). 2021 Mar 28;13(7):
pubmed: 33800656
Sci Rep. 2019 May 28;9(1):7953
pubmed: 31138886
Oncotarget. 2015 May 30;6(15):13772-89
pubmed: 25944696
Front Cardiovasc Med. 2022 Jun 24;9:886689
pubmed: 35811715
Braz J Microbiol. 2009 Jan;40(1):1-11
pubmed: 24031310
J Cancer. 2019 May 21;10(10):2261-2275
pubmed: 31258730
Clin Chem. 2019 Jul;65(7):905-915
pubmed: 30996051
Cell Death Dis. 2018 Apr 27;9(5):472
pubmed: 29700305
Front Endocrinol (Lausanne). 2020 Oct 14;11:567844
pubmed: 33162934
Mol Oncol. 2022 May;16(9):1947-1965
pubmed: 35100495
Nature. 2016 Jan 21;529(7586):298-306
pubmed: 26791720
Cancer Metastasis Rev. 2016 Dec;35(4):645-654
pubmed: 27878502
Eur Rev Med Pharmacol Sci. 2022 Jul;26(13):4659-4665
pubmed: 35856356
Oncol Rev. 2017 May 09;11(1):321
pubmed: 28584570
Front Oncol. 2021 Mar 19;11:620213
pubmed: 33816250
EMBO J. 2021 Feb 1;40(3):e104569
pubmed: 33300180
Exp Hematol. 2002 Sep;30(9):973-81
pubmed: 12225788
Curr Opin Cell Biol. 1997 Jun;9(3):337-42
pubmed: 9159079
RNA Biol. 2021 Oct 15;18(sup1):61-74
pubmed: 34775914
Int J Mol Sci. 2022 Jan 24;23(3):
pubmed: 35163219
Cancer Cell Int. 2019 May 09;19:125
pubmed: 31168298
Nat Rev Dis Primers. 2020 Oct 15;6(1):83
pubmed: 33060614
Oncotarget. 2017 Oct 24;8(55):94834-94849
pubmed: 29212270
Nat Rev Mol Cell Biol. 2020 Oct;21(10):585-606
pubmed: 32457507
Nat Rev Genet. 2019 Feb;20(2):71-88
pubmed: 30410101
Transl Oncol. 2019 Mar;12(3):462-474
pubmed: 30583289
Cancers (Basel). 2019 Feb 23;11(2):
pubmed: 30813457
RNA Biol. 2018 Feb 1;15(2):242-250
pubmed: 29219730
Gynecol Oncol. 2009 Sep;114(3):457-64
pubmed: 19501389
Front Endocrinol (Lausanne). 2022 Sep 29;13:1019864
pubmed: 36246916
Int J Mol Sci. 2020 Aug 15;21(16):
pubmed: 32824183
Oncotarget. 2016 Feb 2;7(5):5131-42
pubmed: 26246471
Front Immunol. 2019 Feb 28;10:202
pubmed: 30873152
Nanomedicine. 2014 Oct;10(7):1517-27
pubmed: 24685946
Annu Rev Biochem. 1995;64:897-934
pubmed: 7574504
Cancer Cell. 2014 Apr 14;25(4):501-15
pubmed: 24735924
Cells. 2019 Jul 15;8(7):
pubmed: 31311206
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
Oncotarget. 2014 Oct 30;5(20):9650-63
pubmed: 25333260
Anticancer Res. 2022 Jul;42(7):3233-3249
pubmed: 35790246
Genes Dev. 2019 Jul 1;33(13-14):741-746
pubmed: 31171702
Int J Mol Sci. 2021 Feb 23;22(4):
pubmed: 33672100
Cells. 2020 Feb 26;9(3):
pubmed: 32111002
Oncogene. 2019 Mar;38(10):1751-1763
pubmed: 30353168
J Cell Mol Med. 2022 Oct;26(20):5150-5164
pubmed: 36056690
Nat Rev Cancer. 2018 Jan;18(1):5-18
pubmed: 29170536
EBioMedicine. 2016 Oct;12:34-42
pubmed: 27720213
Nature. 2005 Dec 8;438(7069):820-7
pubmed: 16341007
Endocr Rev. 2005 Oct;26(6):743-74
pubmed: 15901668
Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):2204-2209
pubmed: 29440427
Cell Death Discov. 2022 Jul 5;8(1):309
pubmed: 35790714
PLoS One. 2016 Nov 10;11(11):e0166284
pubmed: 27832183
J Clin Invest. 2014 Dec;124(12):5109-28
pubmed: 25401471
J Exp Med. 2019 Dec 2;216(12):2883-2899
pubmed: 31548301
Gynecol Oncol. 2008 Jul;110(1):13-21
pubmed: 18589210
Int J Mol Sci. 2020 Sep 25;21(19):
pubmed: 32993038
Mol Cancer. 2014 May 06;13:104
pubmed: 24886050
J Bone Oncol. 2016 Apr 08;5(3):93-95
pubmed: 27761364
Neuropeptides. 2017 Feb;61:87-93
pubmed: 27823858
Nature. 2015 Jun 4;522(7554):106-110
pubmed: 26017313
Cancer Med. 2019 Sep;8(12):5687-5701
pubmed: 31385464
EMBO J. 1998 Jul 1;17(13):3747-57
pubmed: 9649444
Cancer Cell. 2013 Sep 9;24(3):318-30
pubmed: 24029231
Am J Pathol. 1998 Sep;153(3):865-73
pubmed: 9736035
Sci Rep. 2017 Jul 25;7(1):6440
pubmed: 28743979
Oncotarget. 2016 Nov 15;7(46):75571-75584
pubmed: 27765923
Molecules. 2015 Oct 20;20(10):19030-40
pubmed: 26492230
J Biol Chem. 2018 Aug 24;293(34):13284-13296
pubmed: 29980600
Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6243s-6249s
pubmed: 17062708
Sci Rep. 2018 Dec 5;8(1):17650
pubmed: 30518766
Nat Rev Endocrinol. 2011 Apr;7(4):208-18
pubmed: 21200394
J Transl Med. 2019 Aug 8;17(1):259
pubmed: 31395064
Cold Spring Harb Perspect Biol. 2019 Mar 1;11(3):
pubmed: 29959194
Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):12934-12939
pubmed: 29158377
Cancers (Basel). 2022 Jan 30;14(3):
pubmed: 35158995
Nucleic Acids Res. 2016 Jun 20;44(11):5068-82
pubmed: 27174936
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Front Cell Dev Biol. 2020 Nov 03;8:583087
pubmed: 33224949
Science. 2007 Dec 21;318(5858):1931-4
pubmed: 18048652
PLoS Genet. 2017 May 24;13(5):e1006804
pubmed: 28542199
Biomolecules. 2020 May 18;10(5):
pubmed: 32443616
Physiol Rev. 2021 Jul 1;101(3):797-855
pubmed: 33356915
Cancer. 1997 Oct 15;80(8 Suppl):1546-56
pubmed: 9362421
Nat Rev Cancer. 2011 Jun;11(6):411-25
pubmed: 21593787
Cell Death Differ. 2021 Aug;28(8):2450-2464
pubmed: 33742136
Mol Oncol. 2016 May;10(5):693-703
pubmed: 26809501
Cell Death Discov. 2022 May 12;8(1):259
pubmed: 35552378
Genes Dev. 2017 Sep 15;31(18):1847-1857
pubmed: 29021240
Front Genet. 2015 Jan 26;6:2
pubmed: 25674102
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Mol Cancer. 2010 Jul 27;9:198
pubmed: 20663213
Biochem Biophys Res Commun. 2010 Jan 15;391(3):1324-9
pubmed: 20026012
J Immunother Cancer. 2022 May;10(5):
pubmed: 35577506
PLoS One. 2016 Jan 29;11(1):e0148155
pubmed: 26824232
Nat Rev Cancer. 2017 May;17(5):302-317
pubmed: 28303905
Wellcome Open Res. 2018 Sep 19;3:120
pubmed: 30345388
Int J Mol Sci. 2020 Apr 17;21(8):
pubmed: 32316552
BMC Genomics. 2017 Jan 17;18(1):89
pubmed: 28095800
Nucleic Acid Ther. 2013 Jun;23(3):188-94
pubmed: 23656494
Front Oncol. 2021 Feb 05;10:611054
pubmed: 33614495
Biology (Basel). 2021 Aug 20;10(8):
pubmed: 34440039
Cells. 2021 Jul 31;10(8):
pubmed: 34440717
Int J Biochem Cell Biol. 2018 Sep;102:138-150
pubmed: 30053504
PLoS One. 2011;6(6):e20769
pubmed: 21698099
Sci Rep. 2016 Sep 13;6:32651
pubmed: 27623086
Ann Oncol. 2013 Dec;24(12):3128-35
pubmed: 24148817